Ontology highlight
ABSTRACT:
SUBMITTER: Van Der Steen N
PROVIDER: S-EPMC5063481 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
OncoTargets and therapy 20161006
Recently, the development of the third-generation epidermal growth factor receptor-small molecule inhibitor (EGFR-TKI) rociletinib had failed. In this review, the wide-ranging aspects of the evolution of EGFR-TKIs were collected, with a special focus on rociletinib. The influence of different oncogenic mutations on EGFR activity was also discussed. Resistance to the first (erlotinib, gefitinib)- and second (afatinib)-generation EGFR-TKIs provided the rationale behind the development of the third ...[more]